TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15004324

Group type: EXPERIMENTAL
Intervention: Colostrinin (100 microg on alternate days for three weeks followed by two weeks drug-free, repeated three times)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Colostrinin
Number of subjects: 105
Study: 11922396

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1412
Study: 9428993

Group type: EXPERIMENTAL
Intervention: NaCl supplementation (3-5 mmol/kg/day at postnatal ages of 8-21 days; 1.5-2.5 mmol/kg/day at 22-35 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NaCl supplementation (group S)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No NaCl supplementation (group NS)
Number of subjects: 9
Study: 8275216

Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of a diet with 28% of calories as total fat (< 8% saturated fat, up to 9% polyunsaturated fat, 11% monounsaturated fat) and dietary cholesterol intake less than 75 mg/1000 kcal (< 150 mg/d)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Usual-care group provided with a packet of general dietary information
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 663
Study: 2880603

Group type: EXPERIMENTAL
Intervention: ICI 141,292 1 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ICI 141,292 4 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ICI 141,292 (1, 2, and 4 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Atenolol 5 mg
Number of subjects: 14
Study: 30647072

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28079793

Group type: EXPERIMENTAL
Intervention: Dental treatments under general anesthesia (GA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no GA treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (before treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (after treatment)
Number of subjects: 0
Study: 26157242

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 23771604

Group type: EXPERIMENTAL
Intervention: Combined SHA and CMHA services
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Combined BSR-COSP and CMHA services
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: SHA-CMHA trial
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: BSR-COSP-CMHA trial
Number of subjects: 644

Group type: COMPARATOR
Intervention: Regular CMHA services
Number of subjects: 644
Study: 21644306

Group type: EXPERIMENTAL
Intervention: Surround needling plus thin cotton moxibustion
Number of subjects: 80
Study: 19842559

Group type: EXPERIMENTAL
Intervention: Enteral immune nutrition (EIN) enriched with arginine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard enteral nutrition (EN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both EIN and EN groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enteral immune nutrition (EIN)
Number of subjects: 30
Study: 16777536

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including Vietnamese‐language media campaign, lay health worker outreach, Vietnamese Pap clinic, patient registry/reminder system, restoration of a government‐funded low-cost screening program, and continuing medical education for Vietnamese physicians
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Comparison community (Harris County, Texas)
Number of subjects: 2009
Study: 15132723

Group type: EXPERIMENTAL
Intervention: GH treatment (0.5, 1.0, and 1.7 IU/m(2) per day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low dose GH treatment
Number of subjects: 58
Study: 11532054

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 750 U/kg per week subcutaneously from day 5 to day 40
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no erythropoietin)
Number of subjects: 100
Study: 9625225

Group type: EXPERIMENTAL
Intervention: Perceived low control over the stressor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived high control over the stressor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 8156959

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3137026

Group type: EXPERIMENTAL
Intervention: Flumazenil i.v. (0.35 +/- 0.15 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27391356

Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (TPF-E followed by PA-E with XRT)
Number of subjects: 13
Study: 27465189

Group type: EXPERIMENTAL
Intervention: Needle placement within the flexor digitorum profundus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Needle placement within the flexor digitorum superficialis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Needle placement outside both flexors and the sheath
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active range of motion assessment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 48
Study: 25085539

Group type: EXPERIMENTAL
Intervention: Brief Integrated Motivational Intervention plus Treatment As Usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment As Usual alone
Number of subjects: 0
Study: 24373301

Group type: EXPERIMENTAL
Intervention: HAPPY (Healthy and Active Parenting Programme for Early Years) intervention consisting of 12 × 2.5 hr. sessions (6 ante-natal from 24 weeks; 6 postnatal up to 9 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20146063

Group type: EXPERIMENTAL
Intervention: PPV plus low-dose EMP (280 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard-dose EMP (560 mg/day)
Number of subjects: 57
Study: 18490077

Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha2b and ribavirin for 48 weeks
Number of subjects: 19
Study: 16634855

Group type: EXPERIMENTAL
Intervention: Targeted naltrexone (50 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Daily naltrexone (50 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Targeted placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: Daily placebo
Number of subjects: 150
Study: 12383892

Group type: EXPERIMENTAL
Intervention: New localization device
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional flexible wires
Number of subjects: 120
Study: 9882027

Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, all given four times daily) plus omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 195
Study: 8014510

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole (2g)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oral metronidazole (2g)
Number of subjects: 61
Study: 2524679

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 31
Study: 1097035

Group type: EXPERIMENTAL
Intervention: L-histidine 4 g/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31490397

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound added to conventional physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study: 28619227

Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 24071051

Group type: EXPERIMENTAL
Intervention: Fluoroscopy guided caudal epidural steroid injection (CESI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oral non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 46
Study: 21881324

Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (0.2 mg/kg/h until weaning from mechanical ventilation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no sivelestat sodium hydrate)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 18688631

Group type: EXPERIMENTAL
Intervention: Lateral crural steal (LCS) along with placement of a columellar strut and transdomal sutures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard techniques (narrowing transdomal sutures and placing a columellar strut) without LCS
Number of subjects: 60
Study: 17270624

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: TUMT
Number of subjects: 154

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 154
Study: 15505447

Group type: EXPERIMENTAL
Intervention: Cisatracurium infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vecuronium infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cisatracurium and Vecuronium
Number of subjects: 23
Study: 11272721

Group type: EXPERIMENTAL
Intervention: HEP A vaccine (25 units in 0.5 mL)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HEP A & B vaccines concurrently (HEP A: 25 units in 0.5 mL; HEP B: 10 micrograms in 1.0 mL)
Number of subjects: 105

Group type: COMPARATOR
Intervention: HEP B vaccine (10 micrograms in 1.0 mL)
Number of subjects: 105
Study: 9517592

Group type: COMPARATOR
Intervention: Inhaled NO concentration of 20 ppb
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled NO concentrations of 49 ppb, 98 ppb, and 148 ppb
Number of subjects: 10
Study: 8052381

Group type: EXPERIMENTAL
Intervention: Functional rhizotomy from L2-S2 including S2 rootlets
Number of subjects: 85

Group type: COMPARATOR
Intervention: Functional rhizotomy from L2-S1 excluding S2 rootlets
Number of subjects: 85
Study: 2488113

Group type: COMPARATOR
Intervention: Propranolol (PPL) 180-240 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pindolol (PDL) 15-45 mg
Number of subjects: 39
Study: 769949

Group type: EXPERIMENTAL
Intervention: Standard-dose cyclophosphamide (3 mg/kg/day)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose cyclophosphamide (10 mg/kg/day for 4 days out of 14)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (3 mg/kg/day) plus cytosine arabinoside (3 mg/kg/week im)
Number of subjects: 151
Study: 31764989

Group type: EXPERIMENTAL
Intervention: Sodium thiosulphate (NaTS) 25 g/1.73 m2
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 60
Study: 31169558

Group type: EXPERIMENTAL
Intervention: Cytological diagnosis of MPM from pleural fluid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAP1 immunostaining and CDKN2A/p16 fluorescence in‐situ hybridization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine use of prophylactic radiotherapy after pleural interventions
Number of subjects: 0
Study: 28946535

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kinesiotherapy (KIN)
Number of subjects: 40
Study: 25771819

Group type: EXPERIMENTAL
Intervention: 20% SF 6 gas (group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20% SF 6 gas (group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Silicone oil (group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fellow eye (control) for group 1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fellow eye (control) for group 2
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fellow eye (control) for group 3
Number of subjects: 45
Study: 23684157

Group type: EXPERIMENTAL
Intervention: No PPM
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Moderate PPM
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Severe PPM
Number of subjects: 266

Group type: COMPARATOR
Intervention: PPM (overall)
Number of subjects: 266
Study: 21802630

Group type: EXPERIMENTAL
Intervention: Clonidine group (n = 40) received 4.5 mL of lidocaine‐bupivacaine and 0.5 μg/kg of clonidine in a 0.5 mL volume
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40) received a retrobulbar block with 4.5 mL of lidocaine‐bupivacaine and 0.5 mL of saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine group
Number of subjects: 80
Study: 19567926

Group type: EXPERIMENTAL
Intervention: Combined uphill-downhill (U+D) training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Horizontal (H) training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 54
Study: 16877955

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (Nt-proBNP)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 945
Study: 16647884

Group type: EXPERIMENTAL
Intervention: Tiagabine monotherapy (mean daily dose 19.7 mg/day, range 5-35 mg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tiagabine monotherapy
Number of subjects: 34
Study: 12966416

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 0
Study: 10078781

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily for 10 days
Number of subjects: 18
Study: 8542742

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients without complications
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with microvascular disease
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 110
Study: 2318912

Group type: EXPERIMENTAL
Intervention: Organized information presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less-organized information presentation
Number of subjects: 0
Study: 628364

Group type: EXPERIMENTAL
Intervention: Dapotum D minor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study: 31184752

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 295

Group type: COMPARATOR
Intervention: US-RTX
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: US-RTX/CT-P10
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: EU-RTX/CT-P10
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 295
Study: 27555447

Group type: EXPERIMENTAL
Intervention: Foot orthoses with medial arch support and lateral wedge insoles (6° and 10° inclination)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Customized foot orthoses without lateral inclination
Number of subjects: 18

Group type: COMPARATOR
Intervention: Foot orthoses without any additional support
Number of subjects: 18

Group type: COMPARATOR
Intervention: Foot orthoses with medial arch support
Number of subjects: 18
Study: 26056105

Group type: EXPERIMENTAL
Intervention: Intermittent anti-tuberculosis treatment (thrice weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily anti-tuberculosis treatment
Number of subjects: 0
Study: 24000010

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy Nutritional Recommendations (HNR) diet
Number of subjects: 50
Study: 21512411

Group type: EXPERIMENTAL
Intervention: EBTM group (Esomeprazole, Bismuth subcitrate, Tetracycline, Metronidazole)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EBTA group (Esomeprazole, Bismuth subcitrate, Tetracycline, Amoxicillin)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EBTM group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EBTA group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amoxicillin-resistant strains
Number of subjects: 120
Study: 19303891

Group type: EXPERIMENTAL
Intervention: Hydrogen sulphide (H2S) at low concentration (2 ppm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogen sulphide (H2S) at high concentration (8 ppm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoamyl acetate (IAA) at 17.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) at 50% v/v
Number of subjects: 0
Study: 17130343

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C
Number of subjects: 0
Study: 15311720

Group type: EXPERIMENTAL
Intervention: EZE + ATV 10 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: ATV 10 mg
Number of subjects: 246
Study: 11163469

Group type: EXPERIMENTAL
Intervention: Routine pneumococcal conjugate vaccination program
Number of subjects: 3800000
Study: 9067720

Group type: EXPERIMENTAL
Intervention: Sillix Donna (active preparation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8336748

Group type: EXPERIMENTAL
Intervention: Fluticasone (100-200 micrograms/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral prednisone (2.5 to 7.5 mg/day)
Number of subjects: 18
Study: 2946313

Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Continuous infusion of alfentanil
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl and alfentanil
Number of subjects: 19
Study: 31655134

Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks with simplified monitoring
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard monitoring with glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks
Number of subjects: 380
Study: 31556670

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) alone
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU; 12-step facilitation, supportive therapy)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 785

Group type: COMPARATOR
Intervention: A-CRA
Number of subjects: 785
Study: 28586233

Group type: EXPERIMENTAL
Intervention: DentalVibe® Injection Comfort System (DV3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no DV3)
Number of subjects: 60
Study: 25481382

Group type: EXPERIMENTAL
Intervention: Personal coaching, tailored information, and materials (intervention group)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 314
Study: 23458449

Group type: EXPERIMENTAL
Intervention: Complete steroids avoidance (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (n = 50)
Number of subjects: 100
Study: 21272319

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake in GSTM1+ individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (fruit- and vegetable-free basal diet)
Number of subjects: 0
Study: 19329003

Group type: EXPERIMENTAL
Intervention: Single-dose oral azithromycin distributed four times per year to children aged 1-10 years
Number of subjects: 10778

Group type: COMPARATOR
Intervention: Control group (delayed treatment until after the study)
Number of subjects: 10778
Study: 16505178

Group type: EXPERIMENTAL
Intervention: Metoprolol (25 to 200 mg daily)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 14628279

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (500 mg bid) plus didanosine (400 mg qd)
Number of subjects: 187
Study: 11141512

Group type: EXPERIMENTAL
Intervention: Watch, Discover, Think and Act (WDTA) educational program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (children not using the program)
Number of subjects: 76
Study: 9714028

Group type: EXPERIMENTAL
Intervention: Citrate-buffered epoetin alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phosphate-buffered epoetin alpha
Number of subjects: 0
Study: 8296752

Group type: COMPARATOR
Intervention: t-PA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 104
Study: 2805810

Group type: EXPERIMENTAL
Intervention: Naftifine gel 1 percent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naftifine cream 1 percent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Econazole nitrate cream 1 percent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clotrimazole cream 1 percent
Number of subjects: 0
Study: 31515250

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (PEG) therapy
Number of subjects: 115
Study: 28622317

Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy (DCR)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Lid tightening
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Punctoplasty
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Combined group (lid tightening plus punctoplasty)
Number of subjects: 134
Study: 25939019

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Student intervention
Number of subjects: 3245

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3245
Study: 22976131

Group type: EXPERIMENTAL
Intervention: 21/7 regimen (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 21/2 placebo/5 ethinyl estradiol 10 μg regimen (group 2)
Number of subjects: 21